Turn bad into good fat
Enlarge image


Turn bad into good fat

28.04.2013 - Swiss scientists have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

Using mice as model organisms, the research of the team under Christian Wolfrum from ETH Zurich provides a new approach for anti-obesity therapies. For the first time they demonstrated that energy storing white fat cells can be switched to energy-burning brown fat cells.

For their investigations, Wolfrum et al. made use of the observaton that both humans and mice can adapt to cold temperatures by forming brown fat cells within their white fat depots. These so-called "brite" fat cells (brown-in-white) are less common at warmer than at colder temperatures. To demonstrate whether brite fat cells are formed from white fat cells or other precursors the researchers generated mice with genetically labeled specific fat cells. Exposing them to the cold, the mice formed brite fat cells. After warm adaptation the fat tissue turned white again. The experiments proove that white fat cells can convert into brown fat cells and vice versa. As humans have the same type of cells as mice it is likely that the same process occurs in humans upon cold stimulation.

 The researchers now want to find pharmaceutical or nutritional triggers to convert the cells. According to Wolfrum, this would change the current paradigm of obesity treatment. "Current anti-obesity therapies target the energy intake side of the equation by controlling appetite and the uptake of nutrients", says Wolfrum. The pharmacological treatments that are available are not very efficient and usually are associated with side effects. In contrast, this novel approach to treat obesity would target the energy expenditure side of the equation by promoting brown fat formation. 



07.10.2015 T-cell specialist Adaptimmune Therapeutics plc needs more space for its R&D in immuno-oncology. The expanding UK company is building a major facility that will house 200 staff.

Drug DiscoveryGermany

06.10.2015 Evotec has been hired by the US National Cancer Institute (NCI) to provide compound management services to the Chemical Biology Consortium. The goal: the discovery of new cancer treatments.

Drug DevelopmentUKBelgium

01.10.2015 Autoimmune disease specialist Apitope has raised €12m in a Series B financing round and is relocating its UK headquarters to Wales.

Drug DevelopmentFranceEUFinlandSpainItalyAustria

01.10.2015 Paris-based BEAM Alliance, a network of companies working on novel antibiotics founded earlier this year, has released its first position paper.


29.09.2015 Swiss CNS specialist Asceneuron SA has raised CHF30m (€27.5m) in a Series A financing, winning Paris-based Sofinnova Partners as its largest investor.


28.09.2015 US company Aduro Biotech has acquired Dutch monoclonal antibody discovery and development firm BioNovion for €29m plus milestones.


24.09.2015 Nutrition company Nestlé is teaming up with biopharmaceutical company AC Immune SA to develop a Tau diagnostic assay for early Alzheimer’s.


22.09.2015 Bayer has taken another step in its restructuring and development as a life sciences company after splitting from all its chemical divisions.


18.09.2015 AstraZeneca has partnered up with the US Department of Health in order to accelerate the development of new antibiotics. The goal: to be prepared for multi-resistant bugs – and for bioterrorism.


17.09.2015 Another European biotech is coming with a hefty price tag for its US buyer. Amgen Inc. has acquired privatly held Dutch company Dezima Pharma B.V. for US$1.55bn (€1.37bn).


All Events

Current issue

All issues

Product of the week


Stock list

All quotes


  • PHARMING (NL)0.31 EUR19.23%


  • THERAMETRICS (CH)0.04 CHF-33.33%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.13 EUR48.6%
  • OREXO (S)66.00 SEK36.9%
  • ZEALAND PHARMA (DK)156.00 DKK22.4%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • TIGENIX (B)0.88 EUR-27.9%


  • KARO BIO (S)43.60 SEK5282.7%
  • CHRONTECH PHARMA (S)0.35 SEK337.5%
  • GALAPAGOS (B)38.43 EUR225.7%


  • NEOVACS (F)0.70 EUR-77.8%
  • BIOTEST (D)19.15 EUR-74.6%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 08.10.2015